Skip to main content
PMC home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2004 May 28;41(3):544–550. doi: 10.1002/1529-0131(199803)41:3<544::AID-ART21>3.0.CO;2-#

Increased serum levels of cartilage oligomeric matrix protein in chronic erosive arthritis in rats

Carina Vingsbo‐Lundberg 1,✉, Tore Saxne 1, Henric Olsson 1, Rikard Holmdahl 1
PMCID: PMC7159671  PMID: 9506583

Abstract

Objective

To investigate the utility of serum cartilage oligomeric matrix protein (COMP) for disease monitoring in rats with chronic pristane‐induced arthritis, and to examine the influence of age, sex, and genes on COMP concentrations in rat serum.

Methods

Serum COMP levels were quantified by immunoassay. Sera were obtained from DA, E3, and (E3 × DA)F1 rats each week between the ages of 4 and 30 weeks. The (E3 × DA)F2 (second generation after intercrossing) rats were injected intradermally with the synthetic oil pristane. Arthritis was monitored by a macroscopic scoring system, and serum levels of COMP were measured on days 6, 35, and 49 after immunization.

Results

Serum levels of COMP decreased during growth, and reached a plateau after the age of 12 weeks. The DA rats had higher COMP levels than the E3 rats, and the (E3 × DA)F1 rats had intermediate levels. No differences were observed in these levels when the rats were grouped by sex. Arthritic (E3 × DA)F2 rats had increased serum concentrations of COMP on days 35 and 49 after pristane injection (P < 0.0001 versus the nonarthritic animals). COMP levels correlated with the severity of macroscopically detectable arthritis at both time points (r > 0.9). Rats with a chronic disease course were distinguished by higher serum concentrations of COMP during the acute stage than animals with similar clinical scores but with resolving arthritis (P < 0.01).

Conclusion

Serum analyses of COMP offer promise for monitoring tissue involvement in experimental arthritis. Such analyses should be useful for monitoring therapeutic interventions aimed at retarding tissue destruction as well as for studies of the genetically determined regulation of COMP turnover and susceptibility to arthritis. The application of molecular marker measurements to experimental arthritis offers a new possibility for verifying the utility of such measurements in human arthritis.

Supporting information

/cgi-bin/ovid?DOI=10.1002%2F1529-0131%2819983%2941:3<544::AID-ART21>3.0.CO;2-O&ACC=00000889-199803000-00021

References

  • 1. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322: 1277–89. [DOI] [PubMed] [Google Scholar]
  • 2. Saxne T, Heinegård D. Matrix proteins: potentials as body fluid markers of changes in the metabolism of cartilage and bone in arthritis. J Rheumatol 1995;22 Suppl 43: 71–4. [PubMed] [Google Scholar]
  • 3. Thonar EJ‐MA, Shinmei M, Lohmander LS. Body fluid markers of cartilage changes in osteoarthritis. Rheum Dis Clin North Am 1993;19: 635–57. [PubMed] [Google Scholar]
  • 4. Poole AR, Dieppe P. Biological markers in rheumatoid arthritis. Semin Arthritis Rheum 1994;23: 17–31. [DOI] [PubMed] [Google Scholar]
  • 5. Lohmander S, Saxne T, Heinegård D, editors. Molecular markers for joint and skeletal diseases. Acta Orthop Scand 1995; 66 Suppl 266. 7604712 [Google Scholar]
  • 6. Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D, Paulsson M, Rosa‐Pimentel E, et al. Cartilage matrix proteins: an acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992;267: 6132–6. [PubMed] [Google Scholar]
  • 7. DiCesare P, Hauser N, Lehman D, Pasumarti S, Paulsson M. Cartilage oligomeric matrix protein (COMP) is an abundant component of tendon. FEBS Lett 1994;354: 237–40. [DOI] [PubMed] [Google Scholar]
  • 8. Smith RKW, Zunino L, Webbon PM, Bee JA, Heinegård D. Identification of cartilage oligomeric matrix protein (COMP) in equine and bovine tendon. Transcripts of the 41st Annual Meeting of the Orthopaedic Research Society; 1995; Orlando, FL.
  • 9. Recklies AD, Baillargeon L, White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes [abstract]. Arthritis Rheum 1996;39 Suppl 9: S271. [DOI] [PubMed] [Google Scholar]
  • 10. Mörgelin M, Heinegård D, Engel J, Paulsson M. Electron microscopy of native cartilage oligomeric matrix protein purified from the Swarm rat chondrosarcoma reveals a five‐armed structure. J Biol Chem 1992;267: 6137–41. [PubMed] [Google Scholar]
  • 11. Oldberg Å, Antonsson P, Lindblom K, Heinegård D. COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. J Biol Chem 1992;267: 22346–50. [PubMed] [Google Scholar]
  • 12. DiCesare PE, Mörgelin M, Mann K, Paulsson M. Cartilage oligomeric matrix protein and thrombospondin 1: purification from articular cartilage, electron microscopic structure, and chondrocyte binding. Eur J Biochem 1994;223: 927–37. [DOI] [PubMed] [Google Scholar]
  • 13. Barry FP, Gaw JU, Boynton RE, Neame PJ. A keratan sulphate binding protein from cartilage. Transcripts of the 41st Annual Meeting of the Orthopaedic Research Society; 1995; Orlando, FL.
  • 14. Saxne T, Heinegård D. Cartilage oligomeric matrix protein: a novel marker of cartilage detectable in synovial fluid and blood. Br J Rheumatol 1992;31: 583–91. [DOI] [PubMed] [Google Scholar]
  • 15. Månsson B, Carey D, Ionescu M, Rosenberg LC, Poole AR, Heinegård D, et al. Cartilage and bone metabolism in rheumatoid arthritis: differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995;95: 1071–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Sharif M, Saxne T, Shepstone L, Kirwan JR, Elson CJ, Heinegård D, et al. Changes in serum levels of cartilage oligomeric matrix protein (COMP) predict disease progression in osteoarthritis of the knee joint. Br J Rheumatol 1995;34: 306–10. [DOI] [PubMed] [Google Scholar]
  • 17. Petersson IF, Boegård T, Svensson B, Heinegård D, Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol. In press. [DOI] [PubMed]
  • 18. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977;146: 857–68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. Nature 1980;283: 666–8. [DOI] [PubMed] [Google Scholar]
  • 20. Boissier M‐C, Chiocchia G, Ronziere M‐C, Herbage D, Fournier C. Arthritogenicity of minor cartilage collagens (type IX and type XI) in mice. Arthritis Rheum 1990;33: 1–8. [DOI] [PubMed] [Google Scholar]
  • 21. Glant TT, Mikecz K, Arzoumanian A, Poole AR. Proteoglycan‐induced arthritis in BALB/c mice: clinical features and histopathology. Arthritis Rheum 1987;30: 201–12. [DOI] [PubMed] [Google Scholar]
  • 22. Vingsbo C, Sahlstrand P, Brun JG, Jonsson R, Saxne T, Holmdahl R. Pristane induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non‐major histocompatibility complex genes. Am J Pathol 1996;149: 1675–83. [PMC free article] [PubMed] [Google Scholar]
  • 23. Saxne T, Castro F, Rydholm U, Svantesson H. Cartilage derived proteoglycans in body fluids of children: inverse correlation with age. J Rheumatol 1989;16: 1341–4. [PubMed] [Google Scholar]
  • 24. Thonar EJMA, Pachman LM, Lenz ME, Hayford J, Lynch P, Kuettner KE. Age related changes in the concentration of serum keratan sulphate in children. J Clin Chem Clin Biochem 1988;26: 57–63. [DOI] [PubMed] [Google Scholar]
  • 25. Smith RKW. The nature and role of noncollagenous proteins in equine tendon [thesis]. London: Univ. of London; 1997. [Google Scholar]
  • 26. Saxne T, Månsson B. Analysis of body fluid markers of joint metabolism in joint diseases. Osteoarthritis Cartilage. In press.
  • 27. Fex E, Saxne T. Tissue‐derived macromolecules and markers of inflammation in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet. Br J Rheumatol 1997;36: 1161–5. [DOI] [PubMed] [Google Scholar]
  • 28. Larsson E, Mussener Å, Klareskog L, Heinegård D, Saxne T. Serum levels of cartilage oligomeric matrix protein (COMP) and bone sialoprotein (BSP): markers of cartilage and bone involvement in experimental arthritis in rats. Br J Rheumatol. In press. [DOI] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

/cgi-bin/ovid?DOI=10.1002%2F1529-0131%2819983%2941:3<544::AID-ART21>3.0.CO;2-O&ACC=00000889-199803000-00021

Articles from Arthritis and Rheumatism are provided here courtesy of Wiley

RESOURCES